The Experts below are selected from a list of 4020 Experts worldwide ranked by ideXlab platform
Zhongsheng Tong - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the clinical and prognostic features of primary Breast Sarcomas and malignant phyllodes tumor
Japanese Journal of Clinical Oncology, 2015Co-Authors: Fang Wang, Yan Jia, Zhongsheng TongAbstract:Objective: Primary Breast Sarcoma is a kind of extremely rare disease. Malignant phyllodes tumor represents a specific subset of Breast soft tissue tumors. So till now, the classification and clinical management of primary Breast Sarcoma and malignant phyllodes tumor are controversial. The aim of this study is to explore the differences in clinical features, treatment, disease-free survival and overall survival between primary Breast Sarcoma and malignant phyllodes tumor group. Methods: A retrospective review of 35 cases with primary Breast Sarcoma and 70 cases with malignant phyllodes tumor registered from 1995 to 2010 was carried out in Tianjin Medical University Cancer Institute and Hospital. Prognosis in terms of disease-free survival and overall survival was evaluated. Results: In primary Breast Sarcoma group, the result of univariate analysis demonstrated that surgical type, histopathological nodal status and local recurrence were significantly correlated with disease-free survival and overall survival. While, the result of monofactorial analysis showed the tumor size was significant prognostic indicator of disease-free survival and overall survival in malignant phyllodes tumor group. The Kaplan–Meier curves for 5-year disease-free survival rates and overall survival rates demonstrated that no significant difference was found between the primary Breast Sarcoma and malignant phyllodes tumor group (P= 0.702 and 0.772, respectively). Conclusions: The primary Breast Sarcoma patients had identical disease-free survival and overall survival compared with the malignant phyllodes tumor patients, which indicated that primary Breast Sarcoma and malignant phyllodes tumor patients should be treated with the same strategies. Surgical management is important for both the primary Breast Sarcoma and malignant phyllodes tumor patients. The role of the adjuvant radiotherapy and chemotherapy remains uncertain.
Antonio G Nascimento - One of the best experts on this subject based on the ideXlab platform.
-
primary Breast Sarcoma clinicopathologic series from the mayo clinic and review of the literature
British Journal of Cancer, 2004Co-Authors: C Adem, Carol Reynolds, James N Ingle, Antonio G NascimentoAbstract:Primary Sarcomas of the Breast are extremely rare, with less than 0.1% of all malignant tumours of the Breast. Mayo Clinic Surgical Pathology database was searched for all Breast Sarcoma from 1910 to 2000. Pathology reports and slides were reviewed and tumour types were determined. Metaplastic carcinomas and phyllodes tumours were excluded. There were 25 women ranging in age 24-81 years (mean 45 years). All but one patient presented with a palpable lump. Mastectomy was performed in 19 patients and lumpectomy in five patients. Histopathological diagnoses were fibroSarcoma (six), angioSarcoma (six), pleomorphic Sarcoma (six), leiomyoSarcoma (two), myxofibroSarcoma (three), hemangiopericytoma (one) and osteoSarcoma (one). Tumour size ranged from 0.3 to 12 cm (mean 5.7). Low-grade lesions were observed in 10 cases and high-grade in 15. Overall, mean follow-up was 10.5 years. Local recurrence was observed in 11 patients and ranged from 2 to 36 months (mean 15 m), while distant metastasis was observed in 10 patients (40%) affecting lungs, bones, liver, spleen, and skin. Of the 25 patients, 12 have died of disease and six of other causes. Five-year overall (OS) and cause-specific survival (CSS) were 66 and 70%, respectively. OS and DFS at 5 years were 91% for tumours 5 cm. Tumour size was significantly associated with OS (risk ratio=1.3 per 1 cm increase; 95% CI, 1.02-1.7; P=0.036). There was no significant difference in OS or CSS between low- and high-grade lesions. In this series, tumour size was a more valuable prognostic factor than tumour grade.
Fang Wang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of the clinical and prognostic features of primary Breast Sarcomas and malignant phyllodes tumor
Japanese Journal of Clinical Oncology, 2015Co-Authors: Fang Wang, Yan Jia, Zhongsheng TongAbstract:Objective: Primary Breast Sarcoma is a kind of extremely rare disease. Malignant phyllodes tumor represents a specific subset of Breast soft tissue tumors. So till now, the classification and clinical management of primary Breast Sarcoma and malignant phyllodes tumor are controversial. The aim of this study is to explore the differences in clinical features, treatment, disease-free survival and overall survival between primary Breast Sarcoma and malignant phyllodes tumor group. Methods: A retrospective review of 35 cases with primary Breast Sarcoma and 70 cases with malignant phyllodes tumor registered from 1995 to 2010 was carried out in Tianjin Medical University Cancer Institute and Hospital. Prognosis in terms of disease-free survival and overall survival was evaluated. Results: In primary Breast Sarcoma group, the result of univariate analysis demonstrated that surgical type, histopathological nodal status and local recurrence were significantly correlated with disease-free survival and overall survival. While, the result of monofactorial analysis showed the tumor size was significant prognostic indicator of disease-free survival and overall survival in malignant phyllodes tumor group. The Kaplan–Meier curves for 5-year disease-free survival rates and overall survival rates demonstrated that no significant difference was found between the primary Breast Sarcoma and malignant phyllodes tumor group (P= 0.702 and 0.772, respectively). Conclusions: The primary Breast Sarcoma patients had identical disease-free survival and overall survival compared with the malignant phyllodes tumor patients, which indicated that primary Breast Sarcoma and malignant phyllodes tumor patients should be treated with the same strategies. Surgical management is important for both the primary Breast Sarcoma and malignant phyllodes tumor patients. The role of the adjuvant radiotherapy and chemotherapy remains uncertain.
Pasquale Orabona - One of the best experts on this subject based on the ideXlab platform.
-
undifferentiated pleomorphic Sarcoma with osteoclast like giant cells of the female Breast
World Journal of Surgical Oncology, 2013Co-Authors: Giancarlo Balbi, Luca Di Martino, Gianpaolo Pitruzzella, Diego Pitruzzella, Flavio Grauso, Antonella Napolitano, Elisabetta Seguino, Francesco Gioia, Pasquale OrabonaAbstract:The authors describe a case of undifferentiated pleomorphic Sarcoma of the Breast occurring in a 50-year-old woman who presented with a palpable mass in her right Breast. She first noticed the mass one month previously. Core needle biopsy showed connective tissue including epithelioid and spindle cells. The patient underwent total mastectomy without axillary lymph node dissection. Based on examination of the excised tumor, the initial pathologic diagnosis was atypical spindle-shaped and ovoid cells with uncertain malignant potential. Histological findings with immunomarkers led to the final diagnosis of undifferentiated pleomorphic Sarcoma. This case highlights a rare and interesting variant of primary Breast Sarcoma and the important role of immunohistochemistry in defining histological type and differential diagnosis. Hence, undifferentiated pleomorphic Sarcoma has been a diagnosis of exclusion performed through sampling and critical use of ancillary diagnostic techniques.
C Adem - One of the best experts on this subject based on the ideXlab platform.
-
primary Breast Sarcoma clinicopathologic series from the mayo clinic and review of the literature
British Journal of Cancer, 2004Co-Authors: C Adem, Carol Reynolds, James N Ingle, Antonio G NascimentoAbstract:Primary Sarcomas of the Breast are extremely rare, with less than 0.1% of all malignant tumours of the Breast. Mayo Clinic Surgical Pathology database was searched for all Breast Sarcoma from 1910 to 2000. Pathology reports and slides were reviewed and tumour types were determined. Metaplastic carcinomas and phyllodes tumours were excluded. There were 25 women ranging in age 24-81 years (mean 45 years). All but one patient presented with a palpable lump. Mastectomy was performed in 19 patients and lumpectomy in five patients. Histopathological diagnoses were fibroSarcoma (six), angioSarcoma (six), pleomorphic Sarcoma (six), leiomyoSarcoma (two), myxofibroSarcoma (three), hemangiopericytoma (one) and osteoSarcoma (one). Tumour size ranged from 0.3 to 12 cm (mean 5.7). Low-grade lesions were observed in 10 cases and high-grade in 15. Overall, mean follow-up was 10.5 years. Local recurrence was observed in 11 patients and ranged from 2 to 36 months (mean 15 m), while distant metastasis was observed in 10 patients (40%) affecting lungs, bones, liver, spleen, and skin. Of the 25 patients, 12 have died of disease and six of other causes. Five-year overall (OS) and cause-specific survival (CSS) were 66 and 70%, respectively. OS and DFS at 5 years were 91% for tumours 5 cm. Tumour size was significantly associated with OS (risk ratio=1.3 per 1 cm increase; 95% CI, 1.02-1.7; P=0.036). There was no significant difference in OS or CSS between low- and high-grade lesions. In this series, tumour size was a more valuable prognostic factor than tumour grade.